Location of Repository

Glucocorticoids Regulate the Expression of the Human Osteoblastic Endothelin A Receptor Gene

By Irma Börcsök, Hans U. Schairer, Ulrike Sommer, Glenn K. Wakley, Ulrich Schneider, Florian Geiger, Fritz U. Niethard, Reinhard Ziegler and Christian H. Kasperk

Abstract

The endothelial cell–derived peptide endothelin 1 (ET1) stimulates cell proliferation and differentiated functions of human osteoblastic cells (HOC), and HOC constitutively express the endothelin A receptor (ETRA). Therefore, ET1 may play an important role in the regulation of bone cell metabolism. As glucocorticoids (GC) exert a profound influence on bone metabolism and increase the effects of ET1 on bone cell metabolism in vitro, the effects of GC on ETRA expression in HOC were investigated. Dexamethasone (DEX) increased ETRA mRNA levels in a dose- and time-dependent fashion. The effects of dexamethasone, prednisolone, and deflazacort on the increase of ETRA mRNA levels correlate positively with their binding affinity to the GC receptor. Scatchard analysis of ET1 binding data to HOC revealed that DEX increased the binding capacity for ET1 from 25,300 to 62,800 binding sites per osteoblastic cell, leading to an enhanced mitogenic effect of ET1 on HOC after preincubation with DEX. Transiently transfected primary HOC with a reporter gene construct, containing the 5′-flanking region of the ETRA gene fused to luciferase gene, showed a promoter-dependent expression of the reporter gene and the induction of reporter gene expression by DEX treatment. Total RNA extracts of femoral head biopsies with osteonecrotic lesions from GC-treated patients showed threefold higher ETRA mRNA levels compared with extracts of bone biopsies from patients with traumatically induced osteonecrosis and coxarthrosis. Furthermore, GC treatment increased plasma ET1 levels by 50% compared with pretreatment values. These findings suggest that GC induced upregulation of ETRA, and ET1 plasma levels enhance ET1's anabolic action on bone cell metabolism. Increased ET1 concentrations may also impair bone perfusion by vasoconstriction in a metabolically activated skeletal region

Topics: Articles
Publisher: The Rockefeller University Press
OAI identifier: oai:pubmedcentral.nih.gov:2212506
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1997). A new fluorometric assay for determination of osteoblastic proliferation: effects of glucocorticoids and insulin-like growth factor-1. Calcif. Tissue Int.
    2. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
    3. (1989). Bone histomorphometry in glucocorticoid-induced osteoporosis.
    4. (1993). Cell-specific bifunctional role of jun oncogene family members on glucocorticoid receptor-dependent transcription.
    5. (1994). Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Transplantation
    6. (1990). Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy.
    7. (1998). Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells.
    8. (1992). Dexamethasone recruitment of self-renewing osteoprogenitor cells in chick bone marrow stromal cell cultures.
    9. (1997). Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin
    10. (1981). Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone.
    11. (1995). Differential effects of glucocorticoids on human osteoblastic cell metabolism in vitro.
    12. (1983). Effect of glucocorticoids on type I collagen, alkaline phosphatase activity and deoxyribonucleic acid content in cultured rat calvariae.
    13. (1992). Effect of progesterone on the mRNA levels of insulin-like growth factors, IGF-binding proteins and type I- and type II-IGF receptors in human osteoblastic cells.
    14. (1996). Endothelin induces vasoconstriction in the bone vasculature in vitro: an effect mediated by a single receptor population.
    15. Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures.
    16. (1997). Endothelin-1 is a potent regulator of human bone cell metabolism in vitro.
    17. (1991). Endothelin-like immunoreactivity in rat models of diabetes mellitus.
    18. (1987). Gene regulation by steroid hormones.
    19. (1992). Glucocor-1573 Börcsök et al. ticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes.
    20. (1990). Glucocorticoid-induced osteoporosis: pathogenesis and management.
    21. (1997). Glucocorticoidinduced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6.
    22. (1991). Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells.
    23. (1989). Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone.
    24. (1995). Human bone cell phenotypes differ depending on their skeletal site of origin.
    25. (1985). Human bone cells in vitro.
    26. (1998). Inhibition of mitogen-activated protein kinase activity and proliferation of an early osteoblast cell line (MBA15.4) by dexamethasone: role of protein phosphatases.
    27. (1996). Longterm treatment of Swiss 3T3 fibroblasts with dexamethasone attenuates MAP kinase activation induced by insulin-like growth factor-I (IGF-I). Cell Biochem.
    28. (1994). Mechanisms of glucocorticoid action in bone cells.
    29. (1996). Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.
    30. mineral density and blood flow to the lower extremities: the study of osteoporotic fractures.
    31. (1992). Nontraumatic necrosis of bone (osteonecrosis).
    32. (1992). Organization, structure, chromosomal assignment and expression of the gene encoding the human endothelin-A receptor.
    33. (1991). Production of endothelin by smooth muscle cells.
    34. (1996). Progesterone and dexamethasone stimulate proliferation and differentiation of osteoprogenitors and progenitors for adipocytes and macrophages in cell populations derived from adult rat
    35. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms.
    36. (1987). Single step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction.
    37. (1991). Synergistic effects of endothelin-1 and transforming growth factor alpha or epidermal growth factor on DNA replication and G1 to S phase transition.
    38. (1949). The attractions of proteins for small molecules and ions.
    39. (1998). The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension.
    40. (1990). The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides.
    41. (1983). The skeletal tissues.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.